Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy - PubMed (original) (raw)
Review
doi: 10.1038/nrc3670.
Affiliations
- PMID: 24457417
- DOI: 10.1038/nrc3670
Review
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Pierre G Coulie et al. Nat Rev Cancer. 2014 Feb.
Abstract
In this Timeline, we describe the characteristics of tumour antigens that are recognized by spontaneous T cell responses in cancer patients and the paths that led to their identification. We explain on what genetic basis most, but not all, of these antigens are tumour specific: that is, present on tumour cells but not on normal cells. We also discuss how strategies that target these tumour-specific antigens can lead either to tumour-specific or to crossreactive T cell responses, which is an issue that has important safety implications in immunotherapy. These safety issues are even more of a concern for strategies targeting antigens that are not known to induce spontaneous T cell responses in patients.
Similar articles
- Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?
Coulie PG. Coulie PG. Mol Med Today. 1997 Jun;3(6):261-8. doi: 10.1016/S1357-4310(97)01049-6. Mol Med Today. 1997. PMID: 9211417 Review. - Prospects for adoptive T cell therapy.
Yee C, Riddell SR, Greenberg PD. Yee C, et al. Curr Opin Immunol. 1997 Oct;9(5):702-8. doi: 10.1016/s0952-7915(97)80052-0. Curr Opin Immunol. 1997. PMID: 9368780 Review. - Targeting tumours with genetically enhanced T lymphocytes.
Sadelain M, Rivière I, Brentjens R. Sadelain M, et al. Nat Rev Cancer. 2003 Jan;3(1):35-45. doi: 10.1038/nrc971. Nat Rev Cancer. 2003. PMID: 12509765 Review. - Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.
Leko V, Rosenberg SA. Leko V, et al. Cancer Cell. 2020 Oct 12;38(4):454-472. doi: 10.1016/j.ccell.2020.07.013. Epub 2020 Aug 20. Cancer Cell. 2020. PMID: 32822573 Free PMC article. Review. - Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy.
Sensi M, Anichini A. Sensi M, et al. Clin Cancer Res. 2006 Sep 1;12(17):5023-32. doi: 10.1158/1078-0432.CCR-05-2682. Clin Cancer Res. 2006. PMID: 16951217 Review.
Cited by
- Developing Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations.
Phan T, Fan D, Melstrom LG. Phan T, et al. Curr Oncol. 2024 Aug 23;31(9):4855-4884. doi: 10.3390/curroncol31090361. Curr Oncol. 2024. PMID: 39329989 Free PMC article. Review. - T lymphocyte‑related immune response and immunotherapy in gastric cancer (Review).
Zhang Z, Zhang W, Liu X, Yan Y, Fu W. Zhang Z, et al. Oncol Lett. 2024 Sep 6;28(5):537. doi: 10.3892/ol.2024.14670. eCollection 2024 Nov. Oncol Lett. 2024. PMID: 39319215 Free PMC article. Review. - mRNA vaccines: a new era in vaccine development.
Chandra S, Wilson JC, Good D, Wei MQ. Chandra S, et al. Oncol Res. 2024 Sep 18;32(10):1543-1564. doi: 10.32604/or.2024.043987. eCollection 2024. Oncol Res. 2024. PMID: 39308511 Free PMC article. Review. - MDM2 inhibitors in cancer immunotherapy: Current status and perspective.
Zeng Q, Zeng S, Dai X, Ding Y, Huang C, Ruan R, Xiong J, Tang X, Deng J. Zeng Q, et al. Genes Dis. 2024 Mar 28;11(6):101279. doi: 10.1016/j.gendis.2024.101279. eCollection 2024 Nov. Genes Dis. 2024. PMID: 39263534 Free PMC article. Review. - Targeting amino acid-metabolizing enzymes for cancer immunotherapy.
Grobben Y. Grobben Y. Front Immunol. 2024 Aug 14;15:1440269. doi: 10.3389/fimmu.2024.1440269. eCollection 2024. Front Immunol. 2024. PMID: 39211039 Free PMC article. Review.
References
- Cold Spring Harb Symp Quant Biol. 1994;59:617-22 - PubMed
- Cancer Res. 1999 Aug 15;59(16):4100-3 - PubMed
- Int J Cancer. 1998 Aug 12;77(4):538-42 - PubMed
- Cancer Immunol Immunother. 2010 Jun;59(6):943-53 - PubMed
- Clin Dev Immunol. 2010;2010:150591 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources